Pfizer Splits Into 3 Segments In Latest Shakeup

Law360, New York (July 29, 2013, 3:18 PM EDT) -- Pfizer Inc. on Monday said it would shuffle its internal operations to create new business segments focused on brand-name and generic drugs, the latest shakeup for the pharmaceutical giant and a possible precursor to a formal splitting up of the company.

The reorganization will result in three new lines — one devoted to generics and two focused on branded products. One of the branded divisions will be home to therapies involving inflammation, metabolism, neuroscience, pain, rare diseases and gender-specific health, and the other will encompass vaccines,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.